Now accepting applications for 2018 Award
2018 Focus: Contributions to the development and advancement of techniques and approaches for the study of the human microbiome, microbiome-host interactions and interaction between individual microbiome components.
- Alignment with the 2018 Focus: Contributions to the development and advancement of techniques and approaches for the study of the human microbiome, microbiome-host interactions and interaction between individual microbiome components"
- Professor (see FAQ) completed Ph.D. (residency in case of M.D.'s or M.D.- Ph.D.'s) not earlier than January 2008.
- An unrestricted award of a total of $100,000 in support of the professor's research paid to the university in two annual installments.
- 可以选择使用全部或者部分奖金购买安捷伦产品，享受 5 折优惠
- Option to accelerate payments to facilitate procurement of equipment with list price over $100,000
Application Process for 2018:
- 2018 Nomination Form (.doc, 63kb)
The nomination form requires contact information, a summary of the nominee's qualifications and future directions (up to 1000 words), a nomination letter (up to 500 words) and a CV. Self-nominations are encouraged. Please do not include any proprietary information.
- Nomination deadline – February 28, 2018.
- Five finalists will be chosen from the pool of nominees by the Agilent Early Career Professor Award Committee using the criteria above. Finalists are announced by April 30, 2018.
- Finalists are to submit two letters of recommendation addressing why the candidate is an excellent match to the award selection criteria along with a photo. Deadline – May 31,2018.
- The award winner will be announced by July 31, 2018.
- Past and present winners names are posted on the Agilent website along with articles highlighting the principal academic contributions for which the awardees were selected.
2017 Agilent Early Career Professor Award Winner
2017 Focus: Contributions to the development and advancement of techniques for the detection of nucleic acids, proteins, or other biomolecules in the context of Liquid Biopsy and its utilization for early detection, characterization and surveillance of cancer and other diseases and conditions.
Gary J. Patti, Ph.D.
Associate Professor, Department of Chemistry
Arts and Science
Washington University in St. Louis
Dr. Patti received a B.A. in Chemistry and Philosophy from Saint Louis University in 2002 and a Ph.D. in Chemistry from Washington University. He then conducted his Postdoctoral work at the Scripps Research Institute in La Jolla, in Dr. Gary Siuzdak's laboratory from 2008 to 2011. There he was involved in the development of widely used metabolomics informatic resources such as the METLIN metabolite database and XCMS software for data processing.
Dr. Patti joined Washington University as Assistant Professor in 2011, with joint appointments in Chemistry (Arts & Sciences) and Genetics (School of Medicine). His lab has published 51 papers and has received numerous grants and awards. His lab has focused on developing new technologies for following isotope labels in untargeted metabolomics. These isotope-based resources have a rapidly increasing number of uses, including clinical applications. Additionally, his laboratory has created other innovative metabolomic technologies that include a new peak picking algorithm, software for deconvolving contaminated spectra, and a method for removing artifacts. The application of these metabolomic technologies has led to two major biochemical discoveries, the finding of a previously unknown metabolite uniquely increased in patients suffering from chronic pain and the discovery that cancer cells utilize lactate to synthesize a large fraction of their lipids. Lactate has long been thought of as a waste product in fermenting cells, but his lab has shown that it is imported into mitochondria for productive use.
The current major goal of his research program is to continue to develop new metabolomic technologies to overcome current barriers to study human disease and model animals in the context of organismal biology. The innovative solutions that his lab is pursuing rely heavily on measuring stable isotopes incorporated into metabolites, proteins, and DNA by mass spectrometry and are aimed at the identification of metabolic changes in body fluids associated with cancer.
His outstanding work has been recognized by many awards including the Pew Biomedical Scholars award, the Camille Dreyfus award, the Sloan Foundation award, the Mallinkcrodt Scholars awards. (press release)